High Light Drugs And Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
- Paid Up Capital ₹ 0.50 M
- Company Age 32 Year, 6 Months
- Last Filing with ROC 31 Mar 2023
- Revenue Growth -10.50%
- Profit Growth 12.52%
- Ebitda -2.86%
- Net Worth 2.43%
- Total Assets 16.82%
About High Light Drugs And Pharmaceuticals
High Light Drugs And Pharmaceuticals Private Limited (HLDAPPL) is a Private Limited Indian Non-Government Company incorporated in India on 04 August 1992 and has a history of 32 years and six months. Its registered office is in Gwalior, Madhya Pradesh, India.
The Company is engaged in the Chemicals Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.50 M, as per Ministry of Corporate Affairs (MCA) records.
Pradeep Gupta and Rani Gupta serve as directors at the Company.
Company Details
-
Location
Gwalior, Madhya Pradesh, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
-
Website
-
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U24232MP1992PTC007247
-
Company No.
007247
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
04 Aug 1992
-
Date of AGM
21 Sep 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Gwalior
Industry
Who are the key members and board of directors at High Light Drugs And Pharmaceuticals?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Pradeep Gupta
|
Director | 04-Aug-1992 | Current |
|
Rani Gupta
|
Director | 04-Aug-1992 | Current |
Financial Performance of High Light Drugs And Pharmaceuticals.
High Light Drugs And Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 10.5% decrease. The company also saw a substantial improvement in profitability, with a 12.52% increase in profit. The company's net worth moved up by a moderate rise of 2.43%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of High Light Drugs And Pharmaceuticals?
Unlock access to High Light Drugs And Pharmaceuticals's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at High Light Drugs And Pharmaceuticals?
Unlock and access historical data on people associated with High Light Drugs And Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of High Light Drugs And Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped High Light Drugs And Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.